Dialectical Behaviour Group Therapy for Adults With Intellectual Disabilities
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02919826 |
|
Recruitment Status :
Completed
First Posted : September 29, 2016
Results First Posted : May 22, 2020
Last Update Posted : June 2, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Intellectual Disability | Behavioral: Adapted Dialectical Behaviour Therapy | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 20 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Adapting and Evaluating Dialectical Behaviour Group Therapy for Adults With Dual Diagnosis (Intellectual Disabilities With Psychiatric Disorder) |
| Actual Study Start Date : | August 2016 |
| Actual Primary Completion Date : | September 2017 |
| Actual Study Completion Date : | March 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: DBT Group
Adapted Dialectical Behaviour Therapy
|
Behavioral: Adapted Dialectical Behaviour Therapy
12 weekly sessions of DBT group therapy |
|
No Intervention: Control Arm
People in this group will receive treatment as usual
|
- Change in Difficulties in Emotional Regulation Scale (Gratz & Roemner, 2004) [ Time Frame: Pre treatment and 12 week post treatment ]Psychometric measure of emotional dysregulation: Total items 36 (range 36-180), responses ranging from 1 to 5, where 1 is almost never (0-10%), 2 is sometimes (11- 35%), 3 is about half the time (36-65%), 4 is most of the time (66-90%), and 5 is almost always (91-100%). DERS items were recoded so that higher scores in every case indicated greater difficulties in emotion regulation (i.e., greater emotion dysregulation).
- Change in Novaco Anger Scale: Part B (Provocation Index)(Novaco, 2003) [ Time Frame: Pre treatment and 12 week post treatment ]Psychometric measure of anger dyscontrol as part of total anger scale: Total items 25 (range 25-100), responses ranging from 1 to 4, where 1 is not at all angry, 2 is a little angry, 3 is fairly angry and 4 is very angry. NAS-PI were recoded so that higher scores in every case indicated greater difficulties in anger control (i.e., greater anger dyscontrol).
- Change in Reiss Scale of Dual Diagnosis 38Q (IDS, 1987) [ Time Frame: Pre treatment and 12 week post treatment ]Psychometric measure of psychiatric illness in individuals with intellectual disabilities: Total items 26 (range 26-78), responses ranging from 1 to 3, where 1 is no problem, 2 is problem and 3 is always a problem. REISS items were recoded so that higher scores in every case indicated greater problems with mental health issues ( i.e. psychopathology.)
- Change in Adapted Emotion Regulation Checklist (Adapted With Permission From Dante Cicchetti by Jessica Jones) [ Time Frame: Pretreatment and 12 week post treatment ]Psychometric adapted measure of emotional regulation for informants. Given to caregivers to report on changes in observed emotional regulation. Total items 24 (range 24 - 96) responses ranging from 1 to 4, where 1 is never, 2 is sometimes, 3 is often and 4 is almost always. ERC items were recoded so that higher scores in every case indicated greater emotional regulation.
- Global Impression of Change: Percentage of Participants Reporting Improvement [ Time Frame: 12 week Post Treatment ]
Adapted measure of clinical treatment change for informant: Participants were asked for perceived degree of change post group with total overall change; responses ranging from no change (identified problem got worse), to somewhat better (better but no noticeable change), to better (better but the change has not made a significant difference), to moderately better (slight improved difference) to much better (definite improvement and made a significant difference).
GIC items were collapsed either into two groups: no change or change (somewhat better, better, moderately better and much better); responses were analyzed in percentages in either group.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of Mild or Moderate Intellectual Disability
- Symptoms of emotional and behavioural difficulties e.g. emotional dysregulation
- Dedicated caregiver to accompany and attend all sessions
Exclusion Criteria:
- Diagnosis of Autism Spectrum Disorder
- Profound or Severe Intellectual Disability
- Acute psychosis interfering with daily functioning
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02919826
| Canada, Ontario | |
| Division of Developmental Disabilities, 191 Portsmouth Avenue | |
| Kingston, Ontario, Canada, K7M 8A6 | |
| Principal Investigator: | Jessica Jones, PhD | Queen's University, Kingston |
Documents provided by Dr. Jessica Jones, Queen's University:
| Responsible Party: | Dr. Jessica Jones, Principal Investigator, Queen's University |
| ClinicalTrials.gov Identifier: | NCT02919826 |
| Other Study ID Numbers: |
PSIY-511-15 |
| First Posted: | September 29, 2016 Key Record Dates |
| Results First Posted: | May 22, 2020 |
| Last Update Posted: | June 2, 2020 |
| Last Verified: | May 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
Intellectual Disability Neurobehavioral Manifestations Neurologic Manifestations |
Nervous System Diseases Neurodevelopmental Disorders Mental Disorders |

